- Home
- STRO vs HGLB Comparison
STRO vs HGLB Comparison
Compare STRO & HGLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- HGLB
- Stock Information
- Founded
- STRO 2003
- HGLB 1998
- Country
- STRO United States
- HGLB United States
- Employees
- STRO N/A
- HGLB N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- HGLB Trusts Except Educational Religious and Charitable
- Sector
- STRO Health Care
- HGLB Finance
- Exchange
- STRO Nasdaq
- HGLB Nasdaq
- Market Cap
- STRO 172.8M
- HGLB 176.4M
- IPO Year
- STRO 2018
- HGLB N/A
- Fundamental
- Price
- STRO $2.08
- HGLB $7.50
- Analyst Decision
- STRO Strong Buy
- HGLB
- Analyst Count
- STRO 7
- HGLB 0
- Target Price
- STRO $12.14
- HGLB N/A
- AVG Volume (30 Days)
- STRO 1.4M
- HGLB 91.8K
- Earning Date
- STRO 11-13-2024
- HGLB 01-01-0001
- Dividend Yield
- STRO N/A
- HGLB 13.16%
- EPS Growth
- STRO N/A
- HGLB N/A
- EPS
- STRO N/A
- HGLB N/A
- Revenue
- STRO $160,955,000.00
- HGLB N/A
- Revenue This Year
- STRO N/A
- HGLB N/A
- Revenue Next Year
- STRO N/A
- HGLB N/A
- P/E Ratio
- STRO N/A
- HGLB N/A
- Revenue Growth
- STRO 230.90
- HGLB N/A
- 52 Week Low
- STRO $2.04
- HGLB $6.42
- 52 Week High
- STRO $6.13
- HGLB $9.45
- Technical
- Relative Strength Index (RSI)
- STRO 28.56
- HGLB 39.65
- Support Level
- STRO $2.66
- HGLB $7.45
- Resistance Level
- STRO $3.01
- HGLB $7.77
- Average True Range (ATR)
- STRO 0.19
- HGLB 0.09
- MACD
- STRO -0.04
- HGLB -0.02
- Stochastic Oscillator
- STRO 5.64
- HGLB 14.37
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About HGLB Highland Global Allocation Fund
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.